China-Developed Drug License-Out Deal Hits Over $15.5 Billion, Second Largest Ever
Start here
A license-out agreement for a China-developed innovative drug carries a nominal total value exceeding $15.5 billion, making it the second-largest out-licensing deal on record for a China-developed drug. The consideration is structured as a $400 million upfront payment, a $110 million payment due at the one-year anniversary, potential milestone payments exceeding $15 billion, and tiered royalties on sales. The sheer scale of the milestone component places the deal among the largest in the industry's history of China-originated license-outs. No counterparty, target indication or development-stage details have been disclosed in the coverage so far, and confirmation of the deal's execution beyond the announced terms is still pending.
Written by a model from the reports · updated 1 day ago
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comPickChina-Developed Drug Out-Licensing Deal Reaches Over 15.5 Billion Dollars Nominal Value, Second Largest on Record
A license-out deal for a China-developed innovative drug has a nominal total value exceeding 15.5 billion US dollars, ranking second in the history of such out-licensing deals. The consideration includes a 400 million dollar upfront payment, a 110 million dollar one-year anniversary payment, potential milestones exceeding 15 billion dollars, and tiered royalties.
Heat trend for this story
Heat now 3·Peak in the comparable set 7 (Oct 22 08:00)·Change over 24h in the comparable set -50%·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.